[go: up one dir, main page]

JP2004518711A5 - - Google Patents

Download PDF

Info

Publication number
JP2004518711A5
JP2004518711A5 JP2002563920A JP2002563920A JP2004518711A5 JP 2004518711 A5 JP2004518711 A5 JP 2004518711A5 JP 2002563920 A JP2002563920 A JP 2002563920A JP 2002563920 A JP2002563920 A JP 2002563920A JP 2004518711 A5 JP2004518711 A5 JP 2004518711A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2002563920A
Other versions
JP2004518711A (ja
Filing date
Publication date
Priority claimed from GBGB0119435.6A external-priority patent/GB0119435D0/en
Application filed filed Critical
Publication of JP2004518711A publication Critical patent/JP2004518711A/ja
Publication of JP2004518711A5 publication Critical patent/JP2004518711A5/ja
Ceased legal-status Critical Current

Links

JP2002563920A 2001-02-15 2002-02-14 脱髄疾患または脱髄症状の治療方法 Ceased JP2004518711A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26884601P 2001-02-15 2001-02-15
GBGB0119435.6A GB0119435D0 (en) 2001-02-15 2001-08-09 Method of treating of demyelinating diseases or conditions
PCT/US2002/005501 WO2002064126A2 (en) 2001-02-15 2002-02-14 Method of treating of demyelinating diseases or conditions

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009091807A Division JP2009185045A (ja) 2001-02-15 2009-04-06 脱髄疾患または脱髄症状の治療方法
JP2010030929A Division JP2010120958A (ja) 2001-02-15 2010-02-16 脱髄疾患または脱髄症状の治療方法

Publications (2)

Publication Number Publication Date
JP2004518711A JP2004518711A (ja) 2004-06-24
JP2004518711A5 true JP2004518711A5 (ja) 2005-12-22

Family

ID=23024747

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002563920A Ceased JP2004518711A (ja) 2001-02-15 2002-02-14 脱髄疾患または脱髄症状の治療方法
JP2009091807A Abandoned JP2009185045A (ja) 2001-02-15 2009-04-06 脱髄疾患または脱髄症状の治療方法
JP2010030929A Abandoned JP2010120958A (ja) 2001-02-15 2010-02-16 脱髄疾患または脱髄症状の治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009091807A Abandoned JP2009185045A (ja) 2001-02-15 2009-04-06 脱髄疾患または脱髄症状の治療方法
JP2010030929A Abandoned JP2010120958A (ja) 2001-02-15 2010-02-16 脱髄疾患または脱髄症状の治療方法

Country Status (39)

Country Link
US (10) US6967210B2 (ja)
EP (1) EP1368031A2 (ja)
JP (3) JP2004518711A (ja)
KR (3) KR20090005254A (ja)
CN (2) CN100522164C (ja)
AP (1) AP1749A (ja)
AR (1) AR035750A1 (ja)
AU (3) AU2002247200B9 (ja)
BR (1) BR0207272A (ja)
CA (1) CA2438712A1 (ja)
CO (1) CO5390085A1 (ja)
CR (1) CR7023A (ja)
CZ (1) CZ20032172A3 (ja)
EA (2) EA012409B1 (ja)
EC (1) ECSP024218A (ja)
EE (1) EE200300363A (ja)
GB (1) GB0119435D0 (ja)
HK (1) HK1080361B (ja)
HR (1) HRP20030652A2 (ja)
HU (1) HUP0303203A3 (ja)
IL (2) IL157341A0 (ja)
MA (1) MA26152A1 (ja)
ME (1) MEP21208A (ja)
MX (1) MXPA03006110A (ja)
MY (1) MY157745A (ja)
NO (1) NO20033622L (ja)
NZ (4) NZ544720A (ja)
OA (1) OA12549A (ja)
PA (1) PA8540101A1 (ja)
PE (1) PE20040175A1 (ja)
PL (1) PL363638A1 (ja)
SG (1) SG134170A1 (ja)
SK (1) SK10392003A3 (ja)
TR (4) TR200800693T2 (ja)
TW (1) TWI325319B (ja)
UA (2) UA80394C2 (ja)
WO (1) WO2002064126A2 (ja)
YU (1) YU62903A (ja)
ZA (1) ZA200306124B (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
KR20050084445A (ko) * 2002-12-20 2005-08-26 다이노젠 파마세우티컬스, 인코포레이티드 α₂δ 서브유닛 칼슘 채널 모듈레이터를 이용한 무통증방광 질환의 치료방법
US20040209960A1 (en) * 2003-01-30 2004-10-21 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channell modulators
AU2004224322A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
GB0510164D0 (en) * 2005-04-28 2005-06-22 Paradigm Therapeutics Ltd Ion channel
FR2892022B1 (fr) * 2005-10-19 2008-01-04 Urogene Sa Traitement des symptomes de l'irritation de la vessie
FR2892021B1 (fr) * 2005-10-19 2008-01-04 Urogene Traitement de l'incontinence urinaire d'effort et mixte
US8420593B1 (en) * 2006-06-16 2013-04-16 Landon C. G. Miller Compositions and methods for regulating membrane potential
DE102008044844B4 (de) * 2008-08-28 2018-08-30 Siemens Healthcare Gmbh Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes
KR101862539B1 (ko) * 2010-03-26 2018-05-31 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치
US20130184316A1 (en) * 2010-07-15 2013-07-18 Andrew Hornstein Methods for diagnosing and treating concussive disorders
WO2012103471A1 (en) * 2011-01-28 2012-08-02 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
EP3727587A4 (en) * 2017-12-22 2022-02-23 Massachusetts Institute Of Technology COMPOSITIONS AND METHODS FOR THERAPY OF WILLIAMS SYNDROME (WS)
CA3207205A1 (en) * 2021-01-20 2022-07-28 Rush University Medical Center Improved treatment for globoid cell leukodsytrophy or krabbe disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
DE3852335T2 (de) * 1987-04-24 1995-05-11 Hoechst Roussel Pharma N-(Pyridinyl)-1H-indol-1-amine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel.
ES2068294T3 (es) * 1989-08-02 1995-04-16 Hoechst Roussel Pharma 2,3-dihidro-1-(piridinilamino)-indoles, un procedimiento para su preparacion y su uso como medicamentos.
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
EP0731108A1 (en) * 1995-03-10 1996-09-11 Boehringer Mannheim Gmbh Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes
FR2754147B1 (fr) 1996-10-03 2000-02-04 Mbh Technologies Sa Installation et procede pour le traitement de carcasses
DK1056754T3 (da) * 1998-01-29 2004-02-16 Bristol Myers Squibb Co Phosphatderivater af diaryl-1,3,4-oxadiazolon
AU5483500A (en) * 1999-07-09 2001-01-30 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Similar Documents

Publication Publication Date Title
BE2019C547I2 (ja)
BE2019C510I2 (ja)
BE2018C021I2 (ja)
BE2017C049I2 (ja)
BE2018C018I2 (ja)
BE2014C051I2 (ja)
BE2014C041I2 (ja)
BE2014C030I2 (ja)
BE2014C016I2 (ja)
BE2014C015I2 (ja)
BE2013C063I2 (ja)
BE2013C039I2 (ja)
BE2011C038I2 (ja)
JP2003139617A5 (ja)
JP2003026665A5 (ja)
JP2003186329A5 (ja)
JP2003185474A5 (ja)
JP2003203398A5 (ja)
BE2013C046I2 (ja)
JP2004518711A5 (ja)
JP2003210658A5 (ja)
JP2002347049A5 (ja)
JP2003225441A5 (ja)
JP2003203925A5 (ja)
JP2003199307A5 (ja)